Vítek L; Schwertner HA

Idioma: Español
Referencias bibliográficas: 19
Paginas: 94-95
Archivo PDF: 116.96 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007; 43: 1-57.

2. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008; 28: 166-72.

3. Breimer LH, Spyropolous KA, Winder AF, Mikhailidis DP, Hamilton G. Is bilirubin protective against coronary artery disease? Clin Chem 1994; 40: 1987-8.

4. Nicholl P, Mikhailidis D, Hamilton G, Spyropolous LK, Winder AF. Bilirubin and peripheral vascular disease. Br J Surg 1995; 82: 1561-2.

5. Kangas E, Teittinen K, Vilkko P, Utriainen S. Bilirubin and peripheral vascular disease. Br J Surg 1999; 86: 713.

6. Krijgsman B, Mikhailides DP, Winder AF, Hamilton G. Bilirubin and peripheral vascular disease [letter]. Br J Surg 2000; 87: 251-2.

7. Cerne D, Ledinski G, Kager G, Greilberger J, Wang XS, Jurgens G. Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio. Clin Chem Lab Med 2000; 38: 529-38.

8. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 2001; 32: 580-3.

9. Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol 2002; 21: 44-52.

10. Vítek L, Novotný L, Šperl M, Holaj R, Spáil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006; 21: 408-14.

11. Yilmaz FM, Akay H, Duranay M, Yilmaz G, Oztekin PS, Koar U, et al. Carotid atherosclerosis and cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Clin Biochem 2007; 40: 1361-6.

12. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995; 41: 1504-8.

13. Troughton JA, Woodside JV, Young IS, et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007; 14: 79-84.

14. Novotný L, Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Exp Biol Med 2003; 228: 568-71.

15. Vítek L, Jirsa Jr. M, Brodanová M, Kaláb M, Mareek Z, Danzig V, Novotný L, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160: 449-56.

16. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101: 76-82.

17. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22: 437-43.

18. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-6.

19. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006; 43: 1145-51.